A Potent Antibody that Neutralizes All Covid variants.

[imhotep]

An Antibody from Single Human VH-rearranging Mouse Neutralizes All SARS-CoV-2 Variants Through BA.5 by Inhibiting Membrane Fusion.

A research team from the US has announced a mouse model used to generate a VH1-2 heavy chain (HC)- and Vκ1-33 light chain (LC)-based recombinant antibody that broadly neutralized all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the newly emergent Omicron sub-variant BA.5.

Human monoclonal antibodies derived from B cells of patients infected from the early SARS-CoV-2 variants and from vaccinated individuals are rapidly losing their efficacy with the emergence of new Omicron sub-variants. The SARS-CoV-2 spike protein binds to the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell surface. The spike protein is made of non-covalently linked subunits S1, which contains the receptor binding domain (RBD), and S2, which anchors the spike protein and forms the fusion pore after spike protein cleavage.

Humanized mice carrying immunoglobulin genes have earlier yielded monoclonal antibodies that successfully neutralized some of the SARS-CoV-2 variants but have not been developed to yield antibodies that neutralize the Omicron sub-variants.

The present study reports the generation of a broadly neutralizing monoclonal antibody developed using a humanized mouse model carrying single VH1-2 heavy chain (HC) and Vκ1-33 light chain (LC) segments. The SP1-77 antibody differs from previous monoclonal antibodies in the mechanism of SARS-CoV-2 inhibition, as well as the SARS-CoV-2 RBD epitope of binding. The researchers have established a successful prototype for using humanized mouse models carrying VH and Vκ segments to generate a diversity of antibodies and demonstrated the potential of using mouse models to develop humanized antibodies against various pathogens.

PS: Pls see another update below on another set of antibodies discovered by an Israeli team.

 

[jusi]

tfs

 

[Stimulus mind]

TFS, brother

 

[Walter White]

TFS !!!!

 

[Wanniyaz]

TFS!

 

[imhotep]

Update

Another breakthrough has been reported by Tel Aviv University: A team of researchers from the university has demonstrated that antibodies isolated from the immune system of recovered COVID-19 patients are effective in neutralizing all known strains of the virus, including the Delta and the Omicron variants. According to the researchers, this discovery may eliminate the need for repeated booster vaccinations and strengthen the immune system of populations at risk.

It's a continuation of a previous study started October 2020, and the researchers state -
"In the current study, we proved that two other antibodies, TAU-1109 and TAU-2310, which bind the viral spike protein in a different area from the region where most of the antibodies were concentrated until now (and were therefore less effective in neutralizing the original strain) are actually very effective in neutralizing the Delta and Omicron variants. According to our findings, the effectiveness of the first antibody, TAU-1109, in neutralizing the Omicron strain is 92%, and in neutralizing the Delta strain, 90%. The second antibody, TAU-2310, neutralizes the Omicron variant with an efficacy of 84%, and the Delta variant with an efficacy of 97%."

The TAU-1109 and TAU-2310 don't bind to the ACE2 receptor binding site, but to another region of the spike protein - an area of the viral spike that for some reason does not undergo many mutations - and they are therefore effective in neutralizing more viral variants. It's been tested with all the known COVID strains to date.
The two antibodies, cloned in the laboratory at Tel Aviv University, were sent for tests to check their effectiveness against live viruses in laboratory cultures at the University of California San Diego, and against pseudoviruses in the laboratories of the Faculty of Medicine of Bar-Ilan University in the Galilee; the results were identical and equally encouraging in both tests.

These developments will pave the way to effective antibody treatment, without the need to provide booster doses to the entire population every time there is a new variant. Antibodies in the first days following infection can stop the spread of the virus.

 

[kinkon]

බම්ප්